KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Twist Bioscience (TWST) Operating Income (2017 - 2026)

Twist Bioscience has reported Operating Income over the past 10 years, most recently at -$45.9 million for Q1 2026.

  • Quarterly Operating Income fell 10.35% to -$45.9 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$138.8 million through Mar 2026, up 30.99% year-over-year, with the annual reading at -$136.3 million for FY2025, 38.3% up from the prior year.
  • Operating Income was -$45.9 million for Q1 2026 at Twist Bioscience, down from -$32.9 million in the prior quarter.
  • Over five years, Operating Income peaked at -$29.9 million in Q3 2025 and troughed at -$88.9 million in Q2 2024.
  • The 5-year median for Operating Income is -$47.0 million (2023), against an average of -$48.9 million.
  • Year-over-year, Operating Income plummeted 59.99% in 2022 and then skyrocketed 66.13% in 2025.
  • A 5-year view of Operating Income shows it stood at -$44.6 million in 2022, then dropped by 5.26% to -$47.0 million in 2023, then grew by 26.25% to -$34.6 million in 2024, then grew by 5.03% to -$32.9 million in 2025, then plummeted by 39.4% to -$45.9 million in 2026.
  • Per Business Quant, the three most recent readings for TWST's Operating Income are -$45.9 million (Q1 2026), -$32.9 million (Q4 2025), and -$29.9 million (Q3 2025).